Advantage Trust Co Has $147,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Advantage Trust Co boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 52.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 610 shares of the medical instruments supplier’s stock after acquiring an additional 210 shares during the period. Advantage Trust Co’s holdings in Becton, Dickinson and Company were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Crossmark Global Holdings Inc. increased its position in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Crossmark Global Holdings Inc. now owns 10,987 shares of the medical instruments supplier’s stock worth $2,649,000 after acquiring an additional 197 shares in the last quarter. Legacy Capital Wealth Partners LLC lifted its position in shares of Becton, Dickinson and Company by 8.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 2,261 shares of the medical instruments supplier’s stock worth $545,000 after purchasing an additional 171 shares in the last quarter. Axxcess Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 6.0% during the third quarter. Axxcess Wealth Management LLC now owns 9,424 shares of the medical instruments supplier’s stock worth $2,272,000 after purchasing an additional 537 shares during the last quarter. Covestor Ltd grew its position in Becton, Dickinson and Company by 527.2% in the third quarter. Covestor Ltd now owns 715 shares of the medical instruments supplier’s stock valued at $173,000 after purchasing an additional 601 shares in the last quarter. Finally, Atria Investments Inc increased its stake in Becton, Dickinson and Company by 8.0% in the 3rd quarter. Atria Investments Inc now owns 20,049 shares of the medical instruments supplier’s stock valued at $4,834,000 after buying an additional 1,477 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BDX shares. Raymond James decreased their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $4.53 during midday trading on Friday, hitting $231.64. 3,891,353 shares of the company were exchanged, compared to its average volume of 1,084,245. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The firm has a market capitalization of $66.95 billion, a P/E ratio of 47.66, a PEG ratio of 1.80 and a beta of 0.43. The firm’s 50 day moving average price is $237.04 and its two-hundred day moving average price is $235.09. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.42 earnings per share. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is presently 78.19%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.